miR-181d coordinates homologous recombination and anti-tumor immune responses in glioblastoma

iScience 2026 Open access

Read full text
Authors: Gatikrushna Singh, Shilpi Singh, Iteeshree Mohapatra, Jay Hou, Andrew Ni, Debashis Barik, Haoyi Zheng, Stefan Kim, Mayur Sharma, Sean Lawler, Shobha Vasudevan, Efrosini Kokkoli
+7 more Sasmit Sarangi, Heinrich Elinzano, Eric T. Wong, Margot Martinez-Moreno, Ziya Gokaslan, Wafik El-Deiry, Clark C. Chen
DOI: 10.1016/j.isci.2026.115077
Cited by: 2
References: 98

Abstract

. Temozolomide (TMZ) treatment induced cross-resistance to radiation and acquired resistance to TMZ; both forms of resistance were eliminated by RAD51 silencing or miR-181d transfection. Finally, the exogenous introduction of miR-181d in an immunocompetent murine glioblastoma model before radiation treatment induced anti-glioblastoma immune memory. These results support consideration for miR-181d-based glioblastoma therapy.

Fields of Study & Subjects

Glioma Diagnosis and Treatment MicroRNA in disease regulation Neuroinflammation and Neurodegeneration Mechanisms

Publication details

Journal / source
iScience
Publisher
Elsevier BV
Volume
29
Issue
3
Pages
115077–115077
Publication date
18 February 2026
Language
EN